You are here

v.torchilin@northeastern.edu

Profile

Vladimir Torchilin

University Distinguished Professor, Pharmaceutical Sciences
Affiliated Faculty, Bioengineering
Affiliated Faculty, Chemical Engineering
617.373.3206
140 The Fenway, Room 211/214
360 Huntington Avenue
Boston, MA 02115

Biography

The efficacy of drug carriers (including liposomes) can be improved by coating them with certain polymers, thus making them long-circulating. Their properties might be still further improved when they are made targeted by attachment of a target-specific antibody. We are conducting an active research on such long-circulating and targeted pharmaceutical carriers for drugs and diagnostics in a variety of in-vitro and in vivo models. II. Many pharmaceutical micelles easily dissociate in vivo. We proposed to use amphiphilic polyethyleneglycol-lipid conjugates for preparing stable polymeric micelles for non-covalent incorporation and delivery of sparingly soluble drugs and diagnostic agents, and are currently investigating very interesting properties of these micelles in vitro and in vivo. III. We have shown that certain non-pathogenic anti-nuclear autoantibodies with nucleosome-restricted specificity are uniquely reactive against the surface of most tumor but not normal cells. Further studies revealed strong anti-tumor potential of these antibodies towards a broad spectrum of tumors. Being used intravenously in normal physiological concentrations, monoclonal antibody 2C5 dramatically inhibits aggressive EL4 T cell lymphoma and B16 melanoma in mice. We study currently the mechanism of mAb 2C5 action which seems to be connected with an antibody-mediated cellular cytotoxicity.

Education

  • PhD, DSc, MS, Moscow State University

Research & Scholarship Interests

Pharmaceutical biotechnology, drug delivery and targeting, nanomedicine, intracellular and organelle-targeted delivery systems, combination cancer therapy
Affiliated With

Department Research Areas

College Research Initiatives

Selected Publications

  • S. Erdogan, V.P. Torchilin, Gadolinium-Loaded Polychelating Polymer-Containing Tumor-Targeted Liposomes, Methods in Molecular Biology, 1522,   2017, 179-182
  • S.K. Sriraman, G. Salzano, C. Sarosozen, V.P. Torchilin, Anti-Cancer Activity of Doxorubicin-Loaded Liposomes Co-Modified with Transferrin and Folic Acid, European Journal of Pharmaceutics and Biopharmaceutics, 105, 2016, 40-49
  • R. Riehle, B. Pattni, A. Jhaveri, A. Kulkarni, G. Thakur, A. Degterev, V.P. Torchilin, Comination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA, Pharmaceutical Research, 33(7), 2016, 1587-1601
  • T. Wang, B. Narayanaswamy, H. Ren, V.P. Torchilin, Combination Therapy Targeting Both Cancer Stem-Like Cells and Bulk Tumor Cells for Imporved Efficacy of Breast Cancer Treatment, Cancer Biology Therapy, 17(6), 2016, 698-707
  • S.K. Sriraman, J. Pan, C. Sarisozen, E. Luther, V.P. Torchilin, Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR and H69-AR Cells, Molecular Pharmaceutics, 13(2), 2016, 428-437

Related News

July 24, 2017

The Methodist DeBakey Cardiovascular Journal (MDCVJ) reports on leading edge research, diagnosis, and treatments from specialists at the Houston Methodist DeBakey Heart & Vascular Center and...

March 23, 2017

21 COE faculty and affiliates were recipients of FY18 TIER 1 Interdisciplinary Research Seed Grants for 12 different projects representing $600K dollars of investment in research.

March 19, 2015

18 COE faculty and affiliates were recipients of FY16 TIER 1 Interdisciplinary Research Seed Grants for 11 different projects representing over $400K dollars of investment in research.

Related Events